A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates  by Blum, G. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.02099.x
A 1-year Aspergillus terreus surveillance study at the University Hospital
of Innsbruck: molecular typing of environmental and clinical isolates
G. Blum1, S. Perkhofer1, K. Grif1, A. Mayr1, G. Kropshofer2, D. Nachbaur3, R. Kafka-Ritsch4,
M. P. Dierich1 and C. Lass-Flo¨rl1
1Department of Hygiene, Microbiology and Social Medicine, 2Department of Paediatrics, 3Department
of Haematology and Oncology and 4Department of General and Transplant Surgery, Innsbruck
Medical University, Innsbruck, Austria
ABSTRACT
Aspergillus terreus appears to have become an increasingly frequent cause of opportunistic infections in
the University Hospital of Innsbruck (UHI) and is of serious concern because of in vivo and in vitro
resistance to amphotericin B. In order to determine the possible relationship between environmental
contamination by A. terreus and the occurrence of invasive aspergillosis, a 1-year prospective study
(2004–2005) was carried out in the UHI. Isolates obtained from air samples of various high-risk settings
and those from surveillance cultures of proven and probable aspergillosis (EORTC ⁄MSG criteria) were
examined by genotyping. Within 1 year, 34 and 15 A. terreus isolates were collected from the
environment and from patients, respectively. Genotypic analysis with rapid ampliﬁcation of polymor-
phic DNA (RAPD) PCR and the combination of three different primers (R108, CII, P4) revealed 46
distinct genotypic proﬁles (types 1–46). No strain similarity was detected among and within the patients
and environmental areas, indicating a great genomic diversity in A. terreus, which is common in the
environment of Innsbruck and a source of invasive infections in immunosuppressed patients.
Genotypical diversity was found in clinical and environmental A. terreus isolates.
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INTRODUCTION
Invasive fungal infections due to Aspergillus spe-
cies have become a major cause of morbidity and
mortality among immunocompromised patients
[1,2]. Aspergillus fumigatus is most frequently
isolated from clinical specimens, but other species
of clinical importance include Aspergillus ﬂavus,
Aspergillus niger and Aspergillus terreus [3–5].
A. terreus appears to have become an increasingly
frequent cause of opportunistic infections and is
of serious concern because of in vivo and in vitro
resistance to amphotericin B [6]. At the University
Hospital of Innsbruck (UHI), a tertiary-care hos-
pital with c. 2000 beds, infections due to A. terreus
have been noted since 1994 [7]. A laminar airﬂow
unit was instituted in 2000 for patients at risk; this
resulted in a decrease in the incidence of invasive
aspergillosis (IA), but A. terreus infections still
occurred, albeit less frequently. The reason for the
frequency of IA caused by A. terreus at the UHI is
not clear, nor is the reason for the density of
A. terreus in the hospital environment. The molec-
ular typing of Aspergillus has proven useful in
many epidemiological situations. One of the most
widely used genotyping methods for A. terreus is
the random ampliﬁcation of polymorphic DNA
PCR (RAPD PCR), a technically relatively simple
and rapid procedure [8,9].
In this study, the source of A. terreus strains
collected prospectively over a 12-month period
from indoor air of the UHI, outdoor air of
Innsbruck and clinical samples (from colonized
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or infected patients) was investigated. Another
objective was to determine the frequency of
isolation of A. terreus in the air of Innsbruck.
MATERIALS AND METHODS
Environmental monitoring
Between October 2004 and October 2005, environmental
samples were collected prospectively twice weekly inside
and outside the UHI. The haematology unit, the bone marrow
transplant unit, the solid organ transplantation unit and the
paediatric cancer unit were investigated in detail.
All these settings are controlled via highly efﬁcient partic-
ulate air (HEPA) ﬁlter systems. Samples were taken during the
course of normal hospital activity. In parallel, nine places
outside the hospital buildings were screened for A. terreus.
Air sampling was performed with a Surface Air System
Sampler (Admeco-Impactor, Type FH2, Switzerland); samples
of 150 and 100 L were collected inside and outside, respec-
tively. The Surface Air System Sampler was loaded with
autoclaved Sabouraud dextrose agar (SAB) plates, and mea-
surements were made c. 100 cm above the ﬂoor; three speci-
mens per sample collection were taken and incubated at 37C
for 3–5 days. CFUs were counted and extrapolated to CFU ⁄m3
according to the manufacturer’s instructions.
The morphological identiﬁcation of A. terreus and Aspergil-
lus spp. was based on a standard method [10]. Isolates were
preserved at room temperature in 5% glycerol for further
molecular typing.
Patients
Patients hospitalized in the respective settings were screened
for nasal A. terreus colonization twice weekly. Swabs were
taken for inoculation of SAB plates and broth, and processed
further as described above.
Any other clinical A. terreus isolates obtained from patients
suffering from aspergillosis according to EORTC ⁄MSG criteria
were collected and subjected to molecular typing [11].
Molecular genotyping
A. terreus isolates were taken from stock cultures and subcul-
tured on SAB. If there was more than one colony, a mixture of
several colonies from the same specimen was genotyped.
Chromosomal DNA of all isolates was extracted using the
QIAamp Tissue kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. RAPD PCR was performed
with three different primers previously shown to have good
discriminatory power for A. terreus: R108 (5¢-GTATTGCCCT-
3¢), CII (5¢-GCGCACGG-3¢) and P4 (5¢-GATAGATAGATA-3¢)
[9,12]. A 5-lL template containing 50 ng of A. terreus chromo-
somal DNA, 2.5 lL of one primer (20 pmol) and 17.5 lL of
water were mixed with ReadyTo-Go RAPD analysis beads
(Amersham Pharmacia Biotech, Freiburg, Germany) contain-
ing PCR buffer (30 mmol ⁄L KCl, 10 mmol ⁄L Tris-HCl, pH 8.3,
2.5 lg of bovine serum albumin, 3 mmol ⁄L MgCl2,
0.4 mmol ⁄L dNTPs) and 1 unit of Amplitaq DNA polymerase.
Thermocycling was done in a PCR cycler (UNO II; Bometra,
Go¨ttingen, Germany). The PCR products were analysed by
electrophoresis in a 1.8% agarose gel (6 h at 80 V at room
temperature) in 0.5 mmol ⁄L Tris–borate–EDTA running
buffer. The gels were photographed under UV light and
analysed. Highly related strains (groups) were deﬁned as
those having at least 90% homology on the basis of banding
patterns. All experiments were carried out in duplicate to
assess reproducibility.
RESULTS
Environmental and clinical samples
In total, 3498 air samples were collected, 1908
from inside and 1590 from outside the UHI. The
results of species distribution are given in Fig. 1.
The outdoor density of Aspergillus spp. ranged
from 14 to 24.3 CFU ⁄m3 (mean 20.3 CFU ⁄m3),
with an increase from January to April; the
highest density of A. terreus was detected in
February. On average, 4.08 A. terreus isolates
(range 0–8) were collected per month. Inside the
UHI, the annual survey revealed very low fungal
densities (mean 0.037 CFU ⁄m3).
In total, 1873 nasal swabs from 368 patients
were analysed, 442 from patients in the haema-
tology unit, 340 from patients in the bone marrow
transplantation unit, 376 from patients in the
paediatric cancer unit, and 715 from patients in
the surgical transplantation unit. Among all nasal
swabs, 3.7% (taken from 66 patients) were
positive for Aspergillus spp. Only one A. terreus
carrier was identiﬁed; the other carriers had
A. fumigatus. Among those A. fumigatus carriers,
only one patient developed IA; the other patients
suffering from IA were not identiﬁed as nasal
Aspergillus carriers or were not included in the
weekly surveillance project.
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Fig. 1. Concentration of airborne Aspergillus spp. and
Aspergillus terreus conidia (inside and outside) over the
12-month surveillance period (2004–2005).
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Overall, 49 A. terreus isolates were obtained
during this 1-year study period. Thirty and four
A. terreus isolates from outdoors and indoors
were collected, respectively (Table 1).
14 clinical isolates were from patients suffering
from aspergillosis (Table 2) within the study
period.
RAPD typing
Forty-six isolates were genotyped using RAPD
PCR. Recultivation of three outdoor isolates
failed.
Forty-one, 29 and 41 distinct strains were
identiﬁed with the R108, CII and P4 primers,
respectively. After combination of the results
obtained with three different primers, 46 distinct
proﬁles (types 1–46) were identiﬁed (Tables 2
and 3). No similarity was detected among and
within the strains from patients and environmen-
tal strains, indicating great genomic diversity of
A. terreus. RAPD was also performed using the
clinical isolates obtained from 14 sources (Table 2).
DISCUSSION
The present surveillance study shows A. terreus to
be common in the environment of the UHI and to
be common as a cause of aspergillosis in immu-
nocompromised patients in Tirol, Austria. The
genotypic, RAPD-derived proﬁles indicate that
patients were infected with unique strains, mak-
ing a collective source of transmission highly
unlikely.
The composition and concentration of airborne
fungi in external and internal environments have
been the main focus of research [5,8,13,14], as
Aspergillus infections increased signiﬁcantly dur-
ing the last decade. Fungal burden, and genus or
species spread, depend on various factors such as
season, wind speed, temperature and humidity
[15]. In this study, A. fumigatus (97.17%) was
predominant inside the hospital, followed by
A. terreus and A. niger (3.92% each) and A. ﬂavus
(0.98%).
By contrast, Curtis et al. reported A. niger,
Aspergillus candidus, A. ﬂavus and A. fumigatus to
be present inside the hospital [13]. Outside,
A. terreus was present to a lesser extent (1.26%)
but, overall, this species was common in the area
of Innsbruck, as A. terreus was collected at a mean
rate of 4.08 isolates per month. Others did not
detect A. terreus, but showed [14,16,17].
Guinea et al. collected only two A. terreus
strains out of 369 Aspergillus spp. when monitor-
ing air and water [15]. The mean Aspergillus spp.
load of 20.3 CFU ⁄m3 found in this study was
higher than the 6.8 CFU ⁄m3 reported elsewhere
Table 2. Clinical characteristics of patients with Aspergillus terreus infections and rapid ampliﬁcation of polymorphic DNA
(RAPD) types of the corresponding isolates
Patient Sexa Age (years) Disease Source (date)
Primer-derived type
Combined
typebCII P4 R108
1 M 53 Chronic aspergillosisc
(post-transplantation)
Sputum (12 January) E O F 8
Sputum (13 January) J Z U 19
Sputum (18 January) I L O 15
2 M 47 Solid organ transplantationc Sputum (15 March) K Y W 22
Sputum (12 May) K A P 23
Sputum (15 May) L Y P 26
3 M 72 Aspergilloma BAL (27 February) G J N 12
4 M 8 Mucoviscidosis Sputum (1 December) V A H 38
5 F 44 Invasive aspergillosis ⁄CMLc BAL (14 October) N I E 30
6 M 11 Mucoviscidosis Sputum (7 September) Q L G 33
7 M 75 AMLc Sputum (3 March) L D T 25
8 M 53 Larynx cancer Larynx swab (14 September) C P Z 46
9 F 18 Aspergilloma Sputum (16 July) A I B 2
10 F 49 Otitis externa Ear swab (3 August) A I A 1
BAL, bronchial lavage; AML, acute myelogenous leukaemia; CML, chronic myelogenous leukaemia.
aM, Male; F, Female.
bResults of combined analysis of RAPD types produced by primers R108, CII and P4.
cPatients from the surveillance study (negative during screening).
Table 1. Aspergillus terreus and Aspergillus spp. isolates
recovered from air samples during 2004 and 2005
Origin
No. of isolates
A. terreus Aspergillus spp.
Inside Haematology unit 0 8
Organ transplantation unit 2 73
Bone marrow transplantation unit 2 1
Paediatric cancer unit 0 12
Outside Environment 30 >2500
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[13]. This may be explained by ongoing renova-
tion and construction within the UHI during
sample collection. Several studies have conﬁrmed
that renovation leads to a higher density of viable
conidia in the outdoor settings and in non-HEPA
protected areas inside [16,18]. As shown in this
study, HEPA ﬁlter systems reduced the level of
contamination due to Aspergillus spp. inside the
wards.
The lack of aspergilli in the respective risk areas
indicates fungal uptake, most likely prior to hos-
pitalization [19]. However, there is no consensus
concerning the conidial density and the onset of IA.
Rhame reported a higher risk when the average
fungal density inside the hospital was
0.9 CFU ⁄m3 [20].
Arnow et al. noted a marked decrease of infec-
tions when the density fell from 2 to less than
0.2 CFU ⁄m3 [21]. By contrast, two studies found
no correlation between density of airborne asper-
gilli and incidence of IA [14,22].
Patients who are colonized with opportunistic
fungi are at higher risk of developing invasive
disease, and the growth of Aspergillus spp. in
cultures from the nose has been accepted as a
surrogate marker of IA [2,23]. However, the value
of isolating Aspergillus spp. from respiratory tract
specimens is debatable, and it was shown that
37% of humans are colonized with Aspergillus
spp. in deep lung segments without having signs
of infection [19,24,25]. In this study, 3.7% of
patients tested positive for Aspergillus spp. in
nasal specimens, but only one patient developed
aspergillosis due to A. fumigatus. Perfect et al. [26]
made a similar observation, i.e. that most culture
isolates from non-sterile body sites are not indic-
ative of disease.
Surveillance isolates consisted, more or less, of
A. fumigatus. Only one A. terreus carrier (who did
not develop disease) was identiﬁed. Perfect et al.
found A. terreus carriage to be always associated
with invasive disease [26].
The molecular typing of Aspergillus has proven
useful in many epidemiological situations [8].
One of the most widely used genotyping methods
is RAPD PCR, a technically relatively simple and
rapid procedure. Although RAPD PCR has been
criticized for poor reproducibility, this method
has been used successfully for A. terreus isolates,
and primers R108, CII and P4 were found to be
highly discriminatory [5,8,9]. No identical RAPD
proﬁles were found among the strains from the
patients or the environment, indicating great
genetic diversity.
The great genetic diversity might be partly
explained by the limitations of the RAPD
approach. Similar ﬁndings have been observed
for A. fumigatus, but the results depend on meth-
odology and study design [27,28]. One study
described two patients with IA that was caused
by three A. terreus strains of different genotypes, a
phenomenon also described, infrequently, in
patients infected with A. fumigatus [29].
Efforts to identify a common source within the
hospital have been unsuccessful. A. terreus is
endemic in the environment of the UHI,
although to a lesser extent than A. fumigatus.
Worldwide, A. terreus accounts for a minority of
cases of IA, ranging from 1% to 6–12%
[8,26,30,31], and it is a rather common cause of
IA in geographically distant centres, e.g. M.D.
Anderson Cancer Center, Houston, Texas, TX,
USA, University Hospital, Birmingham, Ala-
bama, AL, USA, and UHI, Tirol, Austria [5,32].
The reason for the frequency of IA caused by
A. terreus at the UHI is not clear. Many factors,
Table 3. Rapid ampliﬁcation of polymorphic DNA PCR
typing results for environmental Aspergillus terreus isolates
Date of isolation
(month ⁄ year) Isolate no.
Primer-derived type
Combined
typeCII P4 R108
May ⁄ 2005 36 B I V 3
December ⁄ 2004 6 C J L 4
December ⁄ 2004 7 C K K 5
May ⁄ 2005 39 D K S 6
August ⁄ 2005 41 D X Q 7
January ⁄ 2005 13 E H G 9
April ⁄ 2005 31 F M C 10
April ⁄ 2005 29 F Q B 11
January ⁄ 2005 12 H R J 13
February ⁄ 2005 21 J U N 17
April ⁄ 2005 28 J C K 21
April ⁄ 2005 32 J B J 20
February ⁄ 2005 19 J V M 18
May ⁄ 2005 33 J H A 16
April ⁄ 2005 30 K D K 24
May ⁄ 2005 37 L F O 27
February ⁄ 2005 20 M W L 28
February ⁄ 2005 24 M E M 29
January ⁄ 2005 11 O I H 31
February ⁄ 2005 23 P K D 32
March ⁄ 2005 26 R L G 34
November ⁄ 2004 3 S N Y 35
December ⁄ 2004 8 T C I 36
August ⁄ 2005 43 U G F 37
January ⁄ 2005 14 W N D 39
August ⁄ 2005 44 X T R 40
May ⁄ 2005 34 Y E I 41
October ⁄ 2004 1 Z G E 43
October ⁄ 2004 2 Z B E 42
May ⁄ 2005 35 A M C 44
February ⁄ 2005 16 B F X 45
March ⁄ 2005 N* H S M 14.
Total no. 31 23 28 26 31
N*, nasal carrier.
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such as speciﬁc host-related characteristics, the
state of immunosuppression of the affected
patients, the extensive use of systemic antifungal
agents for prophylaxis and empirical therapy,
and geographical factors, may contribute to this
phenomenon [33].
In summary, A. terreus has become a common
cause of IA and is common in the environment of
the UHI. The genotypic proﬁles indicate that
patients were infected with unique strains, mak-
ing a collective source of transmission highly
unlikely. The onset of A. terreus infection
depends, seemingly, not only on the degree of
immunosuppression, but also on environmental
exposure to Aspergillus spp. Finally, nasal surveil-
lance cultures are not helpful in identifying
patients at risk for A. terreus infections.
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